The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Kisqali reduces risk of cancer recurrence for HR+/HER2- early breast cancer in phase III trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Novartis presented positive primary endpoint data from the phase III NATALEE trial at the 2023 American Society of Clinical Oncology Annual Meeting. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Researchers explore adapted Argentine tango dance therapy for cancer survivors at Ohio State

Adapted Argentine tango dance therapy is helping some breast cancer survivors regain natural balance and sensation after experiencing neuropathy, a common side effect of chemotherapy treatment. Expansion of a new clinical study will look further at how this musical movement intervention can “rewire” the brain to improve function after chemotherapy-related nerve changes.
Clinical Roundup

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account